ADC Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
ADC Therapeutics SA Common Shares (ADCT)
Company Research
Source: Yahoo! Finance
costs, while bolstering the balance sheet via $100M and $60M PIPE financings to support a cash runway into at least 2028. Major clinical catalysts include LOTIS-5 top-line data expected in Q2 2026 (PFS primary endpoint) with a potential supplemental BLA/approval pathway in 2027, and LOTIS-7 showing strong early efficacy (90% BOR, 78% CR) with expanded enrollment. Commercial and financials were roughly stable: Q4 net product revenue was $22.3 million and full-year net product revenue was $73.6 million , while Q4 GAAP net loss improved to $6.4 million and adjusted operating expenses declined year-over-year. Interested in ADC Therapeutics SA? Here are five stocks we like better. ADC Therapeutics (NYSE:ADCT) outlined a 2025 strategy centered on expanding ZYNLONTA while significantly reducing costs, and management pointed investors to multiple clinical and regulatory catalysts expected in 2026 and 2027. Strategy refocused on ZYNLONTA with a lower cost base Chief Executive Offic
Show less
Read more
Impact Snapshot
Event Time:
ADCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADCT alerts
High impacting ADC Therapeutics SA Common Shares news events
Weekly update
A roundup of the hottest topics
ADCT
News
- ADC Therapeutics (ADCT) Reports 2025 Revenue of $73.6M With Cash Runway Into 2028 [Yahoo! Finance]Yahoo! Finance
- ADC Therapeutics SA (ADCT) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic ... [Yahoo! Finance]Yahoo! Finance
- ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- ADC Therapeutics SA (ADCT) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update [Yahoo! Finance]Yahoo! Finance
ADCT
Earnings
- 3/10/26 - Beat
ADCT
Sec Filings
- 3/17/26 - Form EFFECT
- 3/16/26 - Form 424B3
- 3/10/26 - Form S-3
- ADCT's page on the SEC website